Open AccessIndomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats
Author(s) -
Paula Esquivias,
Antonio Morandeira,
Alfredo Escartín,
Carmelo Cebrián,
Sonia Santander,
Francisco J. Esteva,
María Asunción García-González,
Javier Ortego,
Ángel Lanas,
Elena Piazuelo
Publication year - 2012
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v18.i35.4866
Subject(s) - cyclooxygenase , medicine , cox 2 inhibitor , gastroenterology , prostaglandin , prostaglandin e2 , esophagus , adenocarcinoma , histology , intestinal metaplasia , prostaglandin e , anastomosis , esophageal disease , surgery , cancer , enzyme , biology , stomach , biochemistry
To evaluate the effects of indomethacin [dual cyclooxygenase (COX)-1/COX-2 inhibitor] and 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone (MF-tricyclic) (COX-2 selective inhibitor) in a rat experimental model of Barrett's esophagus and esophageal adenocarcinoma.